摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氯-6-氟-3-甲氧基苯甲醛 | 149949-29-1

中文名称
2-氯-6-氟-3-甲氧基苯甲醛
中文别名
——
英文名称
2-chloro-6-fluoro-3-methoxy-benzaldehyde
英文别名
2-Chloro-6-fluoro-3-methoxybenzaldehyde
2-氯-6-氟-3-甲氧基苯甲醛化学式
CAS
149949-29-1
化学式
C8H6ClFO2
mdl
MFCD04115941
分子量
188.586
InChiKey
WRJUPJLEUPNEBO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    267.4±35.0 °C(Predicted)
  • 密度:
    1.334±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氯-6-氟-3-甲氧基苯甲醛硫酸三溴化硼 作用下, 以 二氯甲烷乙腈 为溶剂, 反应 3.5h, 生成 2-chloro-3-[1,2-diamino-2-(2-chloro-6-fluoro-3-hydroxyphenyl)ethyl]-4-fluorophenol
    参考文献:
    名称:
    Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes
    摘要:
    The synthesis and structural characterization of mammary tumor-inhibiting, diastereomeric [1,2-bis(2,6-dihalo-3-hydroxyphenyl) ethylenediamine]platinum(II) complexes with 2,6-Cl2, 2-F, 6-Cl, 2-Cl, 6-F and 2,6-F2 substituents (1-PtSO4 to 4-PtSO4) are described. The related 1,2-diphenylethylenediamines (1-4) are synthesized by stereoselective meso-meso and D,L-D,L diaza-Cope-rearrangement reactions and coordinated to platinum(II) with K2PtI4 (1-PtI2 to 4-PtI2). The subsequent reaction with Ag2SO4 leads to the respective sulfatoplatinum(II) complexes. They were tested for their anti-tumor activities on die hormone-sensitive and- insensitive MXT mammary carcinoma implanted in mice (MXT-MC, ER+ and MXT-MC, ER-). Complexes with F atoms in the neighborhood of the 3-hydroxy group showed strong inhibitory effects on the MXT-MC, ER+. The best effects were found for the diastereomeric 2,6-F2-substituted complexes, meso-4-PtSO4 and D,L-4-PtSO4. These complexes are strongly active both on the MXT-MC, ER+ and the MXT-MC, ER- and cause no estrogenic side effects.
    DOI:
    10.1016/0223-5234(93)90003-w
  • 作为产物:
    描述:
    对氟苯甲醚仲丁基锂 作用下, 以 溶剂黄146 为溶剂, 反应 4.25h, 生成 2-氯-6-氟-3-甲氧基苯甲醛
    参考文献:
    名称:
    Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes
    摘要:
    The synthesis and structural characterization of mammary tumor-inhibiting, diastereomeric [1,2-bis(2,6-dihalo-3-hydroxyphenyl) ethylenediamine]platinum(II) complexes with 2,6-Cl2, 2-F, 6-Cl, 2-Cl, 6-F and 2,6-F2 substituents (1-PtSO4 to 4-PtSO4) are described. The related 1,2-diphenylethylenediamines (1-4) are synthesized by stereoselective meso-meso and D,L-D,L diaza-Cope-rearrangement reactions and coordinated to platinum(II) with K2PtI4 (1-PtI2 to 4-PtI2). The subsequent reaction with Ag2SO4 leads to the respective sulfatoplatinum(II) complexes. They were tested for their anti-tumor activities on die hormone-sensitive and- insensitive MXT mammary carcinoma implanted in mice (MXT-MC, ER+ and MXT-MC, ER-). Complexes with F atoms in the neighborhood of the 3-hydroxy group showed strong inhibitory effects on the MXT-MC, ER+. The best effects were found for the diastereomeric 2,6-F2-substituted complexes, meso-4-PtSO4 and D,L-4-PtSO4. These complexes are strongly active both on the MXT-MC, ER+ and the MXT-MC, ER- and cause no estrogenic side effects.
    DOI:
    10.1016/0223-5234(93)90003-w
点击查看最新优质反应信息

文献信息

  • Benzimidazole Thiophene Compounds
    申请人:Kuntz Kevin
    公开号:US20080300247A1
    公开(公告)日:2008-12-04
    The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
    本发明提供苯并咪唑噻吩化合物及含有该化合物的药物组合物,以及制备该化合物的方法和它们作为药物代理的用途。
  • Phenethyl nicotinamides, a novel class of NaV1.7 channel blockers: Structure and activity relationship
    作者:Inger Kers、Istvan Macsari、Gabor Csjernyik、Martin Nylöf、Karin Skogholm、Lars Sandberg、Alexander Minidis、Tjerk Bueters、Jonas Malmborg、Anders B. Eriksson、Per-Eric Lund、Elisabet Venyike、Lei Luo、Jan-Erik Nyström、Yevgeni Besidski
    DOI:10.1016/j.bmcl.2012.08.031
    日期:2012.10
    and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable
    Na V 1.7离子通道是潜在的止痛药开发的一个有吸引力的目标,它基于通道蛋白编码基因的突变与可遗传的疼痛状况之间的牢固遗传联系。的(小号) - ñ -苯并二氢吡喃-3-基羧系列,通过举例说明1,被用作新的通道阻滞剂发展的起始点,导致苯乙烟酰胺系列。建立了该系列的结构和活性之间的关系,并通过适当的替代解决了早期类似物的代谢问题。化合物33显示出可接受的总体体外特性和体内大鼠PK谱。
  • BENZIMIDAZOLE THIOPHENE COMPOUNDS
    申请人:Kuntz Kevin
    公开号:US20100075960A1
    公开(公告)日:2010-03-25
    The present invention provides bezimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
    本发明提供了苯并咪唑噻吩化合物,包含这些化合物的药物组合物,制备这些化合物的方法以及它们作为药物的用途。
  • IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS
    申请人:Olsson Roger
    公开号:US20110206607A1
    公开(公告)日:2011-08-25
    Disclosed herein are compounds of Formula (I), or a pharmaceutically acceptable salt, ester, amide, thereof; and methods of modulating the activity of a cannabinoid CB2 receptor comprising contacting a compound of Formula I with the cannabinoid CB2 receptor. Also disclosed are methods of imaging of a tissue by positron emission tomography, the method comprising administering to the subject a compound of Formula I, wherein the compound comprises a radioisotope. Also disclosed are methods of measuring the relative concentration of cannabinoid CB2 receptors in tissue of a subject, by using a compound of Formula I which comprises a radioisotope. In addition, method of diagnosing a disorder in a subject are disclosed.
    本文公开了I式化合物,或其药学上可接受的盐、酯、酰胺等;以及调节大麻素CB2受体活性的方法,包括将I式化合物与大麻素CB2受体接触。还公开了通过正电子发射断层扫描成像组织的方法,该方法包括向受试者注射I式化合物,其中该化合物包含放射性同位素。还公开了通过使用含有放射性同位素的I式化合物来测量受试者组织中大麻素CB2受体的相对浓度的方法。此外,还公开了一种诊断受试者疾病的方法。
  • BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON PLK
    申请人:GlaxoSmithKline LLC
    公开号:EP2032563B1
    公开(公告)日:2010-06-02
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐